<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931992</url>
  </required_header>
  <id_info>
    <org_study_id>202100042</org_study_id>
    <nct_id>NCT04931992</nct_id>
  </id_info>
  <brief_title>Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.</brief_title>
  <acronym>MOLAM</acronym>
  <official_title>Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite good initial response, some patients with core binding factor and/or NPM1-mutated AML&#xD;
      eventually relapse. Some of these patients can be identified earlier on, before overt&#xD;
      cytological relapse, when followed for minimal residual disease. The outcome of patients&#xD;
      treated when molecular relapse is confirmed, before overt cytological relapse, is not well&#xD;
      known. This multi-center retrospective will therefore study the outcome of these patients and&#xD;
      try to specify the role of allogeneic stem cell transplantation in this setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Molecular relapse</arm_group_label>
    <description>Confirmed molecular relapse, without overt cytological relapse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytological relapse</arm_group_label>
    <description>Overt cytological relapse, without prior molecular relapse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Persistent responders</arm_group_label>
    <description>No molecular or cytological relapse during follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Retrospective analysis</description>
    <arm_group_label>Cytological relapse</arm_group_label>
    <arm_group_label>Molecular relapse</arm_group_label>
    <arm_group_label>Persistent responders</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients &lt; 61 years with CBF and/or NPM1-mutated AML in CR1 after induction therapy&#xD;
        who did not receive allogeneic stem transplantation and who were followed for measurable&#xD;
        residual disease after completion of treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18 and 61 years&#xD;
&#xD;
          -  Diagnosis between 2010 and 2019&#xD;
&#xD;
          -  Core binding factor and/or NPM1 acute myeloid leukemia&#xD;
&#xD;
          -  First complete remission after induction therapy&#xD;
&#xD;
          -  Measurable residual disease measurement after end of consolidation therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia&#xD;
&#xD;
          -  Allogeneic stem cell transplantation in CR1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Corentin Orvain, MD, PhD</last_name>
    <phone>+33241354475</phone>
    <email>corentin.orvain@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corentin Orvain, MD, PhD</last_name>
      <phone>+33241354475</phone>
      <email>corentin.orvain@chu-angers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

